Why the study?
Does alogliptin prevent the progression of carotid atherosclerosis in patients with type 2 diabetes mellitus free of apparent cardiovascular disease?
Population
341 patients with type 2 diabetes mellitus (T2DM) free of a history of apparent cardiovascular diseases
Comparison
Alogliptin vs Conventional treatment
Design
RCT, randomly allocated, open-label, blinded-end point
Follow-up
24 months
Authors
Loading...
Alogliptin attenuates carotid IMT progression in T2DM without CVD; extends RCT evidence on this vascular surrogate.
Does alogliptin prevent the progression of carotid atherosclerosis in patients with type 2 diabetes mellitus free of apparent cardiovascular disease?
Alogliptin significantly attenuated the progression of carotid intima-media thickness compared to conventional treatment in patients with type 2 diabetes without apparent cardiovascular disease.
Mita et al. (2015) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: